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costs exceeded the weighted DRG cost by €1396 for the public
and €813 for the private hospital. Overall endophtalmitis costs
were euro 4125. Using DRG 60 (Severe acute ocular infections)
as a proxy of endophthalmitis would underestimate dramatically
(>45%) its cost. Endophthalmitis expenses were estimated at
€6,509,000 for the French Health Care System. CONCLUSION:
Using DRG 60 as a proxy of endophthalmitis in health eco-
nomics evaluation to estimate the hospital true cost is inappro-
priate The PMSI clustering algorithm underestimates the budget
allocation required to treat endophtalmitis in the public and
private sectors. The PMSI (reporting exhaustively all hospitali-
sations) could be used to better capture the yearly endoph-
thalmitis incidence rate.
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OBJECTIVE: The aim of the study was to estimate the preva-
lence of patients treated with antiglaucoma agents for glaucoma
or ocular hypertension in France, and the cost of treatment over
one year. METHOD: Prevalence was estimated using a per-
manent panel of subjects afﬁliated to a French national health
insurance scheme, the EPAS panel. Patients with glaucoma or
ocular hypertension (OHT) were identiﬁed by the prescription
of antiglaucoma preparations and miotics (ATC code S01E).
Chronic patients were deﬁned as those who had been prescribed
at least three boxes during the year. The three years 2001, 2002
and 2003 were studied to check the stability of estimations. The
cost of treating ambulatory patients was estimated using data
from the EPAS panel on consultations, specialist procedures and
drug prescriptions. The cost of inpatient care over the three years
2001 to 2003 in public and private hospitals for patients with a
principal diagnosis of glaucoma was estimated using PMSI data
(a French system of recording hospital procedures performed on
given patient groups), the French national cost study and the
approved tariffs for the private sector. RESULTS: The estimated
prevalence was stable over 3 years, between 1.1 to 1.2 million
patients. The average age of patients was 71 years for women
and 67 for men. The average cost, for social security, per patient
for ambulatory care was €291 in 2003, €204 of which was for
drug prescriptions. About 1.2% of patients were hospitalised
and the average cost per patient was €26. In one in three cases,
glaucoma surgery was accompanied by lens surgery. The total
spending on treatment in 2003 was €382 million. CONCLU-
SION: The study conﬁrms that glaucoma is a major eye disease.
The cost of disease across three years seems to be stable.
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OBJECTIVE: Licensing and reimbursement decisions for age-
related macular degeneration (AMD) therapies may be driven by
different cost and outcome relationships across payers and thus
any model should be ﬂexible to accommodate these vari-
ances transparently. METHODS: To accurately assess cost-
effectiveness of treatment as desired by European countries, a
comprehensive model considering all direct costs is important. A
Markov framework was used to model a cohort’s lifetime move-
ment through visual acuity (VA) states of >20/40, 20/40 to
>20/80, 20/80 to >20/200, 20/200 to >20/400, and >20/400. Pre-
senting lesion subtypes (i.e., predominately classic, minimally
classic, and occult) were considered. Unlike previous models,
patients could experience more than one gain or loss of VA over
their lifetimes. This comprehensive model was initially populated
from a US perspective. Drug, procedure, monitoring, outpatient,
vision rehabilitation, and adverse events (AEs) costs were
obtained from standard US published sources. Expert interviews
were conducted to determine AE treatment patterns and vision
rehabilitation resource use. Relative risks and costs associated
with effects associated with declining VA were extracted from a
Medicare analysis. Efﬁcacy data was taken from published liter-
ature for two years of treatment for all lesion subtypes. Efﬁcacy
beyond two years was extrapolated from clinical trials. Utilities
were taken from similar published sources as previous models.
RESULTS: Results are expressed as vision years, quality-adjusted
life years (QALYs), drug, treatment, AE, and other costs as well
as incremental cost per vision year and QALY gained. Outcomes
were discounted 3% per annum. This model is more robust than
previous models as patient movement is not limited and repre-
sents natural disease progression over a lifetime, costs attributed
to declining VA are included, and all lesion subtypes have been
analyzed. CONCLUSIONS: Thus, cost-effectiveness of treat-
ment of AMD with respect to differing licensing and reimburse-
ment is more accurately analyzed.
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OBJECTIVES: While standard gamble and time trade off are
commonly used to estimate quality weights within the Quality
Adjusted Life Year (QALY) framework, a potentially useful tech-
nique is discrete choice experiments (DCEs). Whilst DCEs have
been extensively used in health economics, their application to
estimate quality weights is limited. Here we report the results 
of a study using the DCE methodology to derive a utility scale
for patients with glaucoma. METHODS: Based on qualitative
research, literature reviews, expert opinion and validated proﬁle
tools, a 6-dimensional glaucoma proﬁle outcome measure was
developed. The six dimensions were: “central and near vision”,
“lighting and glare”, “outdoor mobility”, “activities of daily
living”, “local eye discomfort” and “other effects of glaucoma
and its treatment”. Levels assigned to each dimension were: “no
difﬁculty”; “some difﬁculty”; “quite a lot of difﬁculty” and
“severe difﬁculty”. Experimental design techniques, ensuring the
properties of orthogonality, minimum overlap and level balance,
were used to derive a sample of the outcome states for which
preferences were elicited. A face-to-face questionnaire was
administered to subjects from clinics in Aberdeen and Leeds. In
addition, a postal questionnaire was sent to patients with glau-
coma, self selected from the International Glaucoma Association.
Response data were analysed using logistic regression tech-
niques. RESULTS: Weights were estimated for all parameters of
the model (all levels of all dimensions), and from this a nor-
malised utility score was estimated, anchored between zero
(worst level of all attributes) and one (best level of all attributes).
